Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.
Dis Markers. 2013;35(5):301-10. doi: 10.1155/2013/715472. Epub 2013 Sep 15.
Endothelial-derived microparticles (EDMPs) and platelet-derived microparticles (PDMPs) have been reported to be increasing in various diseases including malignant diseases. Here, we investigated whether these MPs may be useful biomarkers for predicting lung cancer (LC) disease status, cell type, or metastasis.
One hundred and thirty LC patients were prospectively enrolled into the study between April 2011 and February 2012. Flow cytometric analysis demonstrated that the circulating levels of platelet-derived activated MPs (PDAc-MPs), platelet-derived apoptotic MPs (PDAp-MPs), endothelial-derived activated MPs (EDAc-MPs), and endothelial-derived apoptotic MPs (EDAp-MPs) were significantly higher in LC patients than in 30 age- and gender-matched normal control subjects (all P < 0.05). Additionally, circulating level of PDAc-MPs was significantly lower (P = 0.031), whereas the circulating levels of the other three biomarkers did not differ (all P > 0.1) in early stage versus late stage LC patients. Furthermore, the circulating levels of the four types of MPs did not differ among patients with different disease statuses (i.e., disease controlled, disease progression, and disease without treatment, i.e., fresh case) (all P > 0.2) or between patients with or without LC metastasis (all P > 0.5). Moreover, only the circulating level of EDAp-MPs was significantly associated with the different cell types (i.e., squamous cell carcinoma, adenocarcinoma, and small cell carcinoma) of LC (P = 0.045).
Circulating MP levels are significantly increased in LC patients as compared with normal subjects. Among the MPs, only an increased level of EDAp-MPs was significantly associated with different LC cell types.
已有研究报道，内皮细胞来源的微颗粒（EDMPs）和血小板来源的微颗粒（PDMPs）在包括恶性肿瘤在内的各种疾病中增加。在这里，我们研究了这些微颗粒是否可作为预测肺癌（LC）疾病状态、细胞类型或转移的有用生物标志物。
2011 年 4 月至 2012 年 2 月，前瞻性纳入 130 例 LC 患者入组研究。流式细胞术分析显示，LC 患者循环血小板源性激活微颗粒（PDAc-MPs）、血小板源性凋亡微颗粒（PDAp-MPs）、内皮源性激活微颗粒（EDAc-MPs）和内皮源性凋亡微颗粒（EDAp-MPs）的水平明显高于 30 例年龄和性别匹配的正常对照者（均 P < 0.05）。此外，早期 LC 患者循环 PDAc-MPs 水平明显降低（P = 0.031），而其他 3 种生物标志物的循环水平在早期和晚期 LC 患者之间无差异（均 P > 0.1）。此外，不同疾病状态（即疾病控制、疾病进展和未经治疗，即新发病例）的患者之间 4 种微颗粒的循环水平无差异（均 P > 0.2），或有或无 LC 转移的患者之间循环水平无差异（均 P > 0.5）。此外，仅 EDAp-MPs 的循环水平与 LC 的不同细胞类型（即鳞癌、腺癌和小细胞癌）显著相关（P = 0.045）。
与正常对照者相比，LC 患者的循环微颗粒水平显著升高。在这些微颗粒中，仅 EDAp-MPs 水平升高与 LC 的不同细胞类型显著相关。
